💥Game-changer in small cell #lungcancer! #ESMO26 LBA3 DeLLphi-305: Tarlatamab + durvalumab vs durvalumab 1L maintenance in ES-SCLC (n=563) after chemo-IO. Median OS ⬆️ 21.1 vs 12.7 mo (HR 0.42), PFS ⬆️7.4 vs 1.9 mo (HR 0.34), ORR 26% vs 4%. ☢️44% of pts still on T+D due to #radiotherapy of oligoprogressive sites? #SCLC #LCSM @NEJM ➡️ https://shorturl.at/IiOO1
204 浏览 · 7 赞 · 2 转发 · 1 回复
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- Mark Storey@ProtonStorey
@_ShankarSiva @sands_jacob @bensolomon1 @jryckman3 @DrJNaidoo @StephenVLiu @NarjustFlorezMD @peters_solange @tnewsomdavis @DrRiyazShah @bslotman Based on curves and censor marks, I bet it strengthens with longer followup. I think the means might understate the impact. Impressive progress for this cohort
来源：Shankar Siva · x.com